3 Reasons to Buy CRISPR Therapeutics Stock, and 1 Reason to Sell
CRISPR Therapeutics (NASDAQ: CRSP) is one of the most innovative biotechs out there, and that means there's no shortage of reasons to consider buying its stock. But much like its peers, it's a high-risk investment until it gets its first medicine out the door and onto the market.
So, is this is a compelling opportunity for your portfolio or a potential source of fool's gold? Let's examine a trio of reasons to buy this stock, and one key reason to consider selling it if you're a holder right now.
CRISPR's cell therapies are incredibly sophisticated even though they're still in clinical trials. And in biotech, having a more sophisticated approach is often the only way to ensure that a medicine performs better than the alternatives that are already on the market -- assuming there's a way to treat the target condition with a less-complicated approach at all.
Source Fool.com
